| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-synuclein levels in the blood and brain
* Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany;
Physiology Weihenstephan, Technical University Munich, Freising-Weihenstephan, Germany; and
Department of Behavioural Ecology and Evolutionary Genetics, Max Planck Institute for Ornithology, Starnberg (Seewiesen), Germany
2Correspondence: Hertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Hoppe-Seyler Str. 3, 72076 Tübingen, Germany. E-mail: thomas.gasser{at}med.uni-tuebingen.de
Genetic variability in the promoter and 3' region of the SNCA gene coding 
-synuclein modulates the risk to develop sporadic Parkinson’s disease (PD). Whether this is mediated by regulating -synuclein expression levels remains unknown. Therefore, we analyzed levels of -synuclein in blood and human post mortem brain tissue including the substantia nigra using quantitative real-time reverse transcriptase-polymerase chain reaction and enzyme linked immunosorbent assay in vivo. Single nucleotide polymorphism (SNP) rs356219, a tagging SNP for a disease-associated haplotype in the 3' region of the SNCA gene, has a significant effect on SNCA mRNA levels in the substantia nigra and the cerebellum. Further, the "protective" genotype 259/259 of the PD-associated promoter repeat NACP-Rep1 is associated with lower protein levels in blood than genotypes 261/261, 259/261, and 259/263. In conclusion, we provide evidence that -synuclein levels are influenced by genetic variability in the promoter and 3' region of the SNCA gene in vivo.—Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., Berg, D., Mueller, J. C., Gasser, T. Genetic variability in the SNCA gene influences -synuclein levels in the blood and brain.
Key Words: Parkinson’s disease • SNP • NACP-Rep1 • substantia nigra • gene expression • real-time RT-PCR • ELISA
This article has been cited by other articles:
|
|
 |
|
  J. Tong, H. Wong, M. Guttman, L. C. Ang, L. S. Forno, M. Shimadzu, A. H. Rajput, M. D. Muenter, S. J. Kish, O. Hornykiewicz, et al. Brain {alpha}-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation Brain, January 1, 2010; 133(1): 172 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Savica, B. R. Grossardt, J. M. Carlin, M. Icen, J. H. Bower, J. E. Ahlskog, D. M. Maraganore, D. P. Steensma, and W. A. Rocca Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study Neurology, October 27, 2009; 73(17): 1381 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Cronin, D. Ge, P. Manninger, C. Linnertz, A. Rossoshek, B. M. Orrison, D. J. Bernard, O. M.A. El-Agnaf, M. G. Schlossmacher, R. L. Nussbaum, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human {alpha}-synuclein in transgenic mouse brain Hum. Mol. Genet., September 1, 2009; 18(17): 3274 - 3285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gasser Genomic and proteomic biomarkers for Parkinson disease Neurology, February 17, 2009; 72(7_Supplement_2): S27 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Westerlund, A. C. Belin, A. Anvret, A. Hakansson, H. Nissbrandt, C. Lind, O. Sydow, L. Olson, and D. Galter Cerebellar {alpha}-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material FASEB J, October 1, 2008; 22(10): 3509 - 3514. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
